skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration

weekly audio catch-up on global biopharma developments

Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by Scrip's global team, in this podcast version of Five Must-Know Things.

This episode covers insights for the business week ended 7 January 2022, including: new mRNA deal for Pfizer Inc. and BioNTech SE; court ruling helps Novartis AG’s Gilenya; first cut-price generic Paxlovid launched; breaking down BridgeBio Pharma, Inc.’s Phase III failure; and a look at gene editing companies to watch at JP Morgan.

This and all our other podcasts are available on the Informa Pharma Intelligence channel on Apple PodcastsGoogle PodcastsSoundCloudTuneIn and Spotify Podcasts, and via smart speakers if one of these platforms has been set up as your default podcast provider.  

Stories mentioned in this episode:

(BioNTech Deal Shows Pfizer Is Reinvesting COVID-19 Windfall In mRNA)
 
(Novartis MS Franchise Boosted After Fending Off Last Gilenya Challenge)

(Beximco Delivers First Cut-Price Generic Paxlovid)

(Stock Watch Bridgebios Endpoint A Bridge Too Far)

(GeneEditing Companies To Watch At JP Morgan)

 

Read also

;

Next steps

Whether you’re a small biotech start-up, research firm, generic manufacturer or a global pharmaceutical giant, you need focused, independent insight and opinion on market developments.

Our team is ready to hear from you for a particular request or area of interest. Please do not hesitate to reach out and discuss.

Contact us for product technical and account support.

  • US Toll-Free   : +1 888 670 8900 
  • US Toll             : +1 212-600-3520
  • UK & Europe : +44 (0) 208 052 0700

Have an immediate and specific information need?

Browse and buy from 1000s of analysis and research reports now: